'Meet people where they are:' local health departments key to hepatitis B vaccination

November 17, 2020

In 2018, West Virginia had the highest rate of acute hepatitis Brate of acute hepatitis B in the nation. That same year, the state had the highest rate of opioid prescriptions per 100,000 people. That's not a coincidence: drug use--including opioid misuse--raises a person's risk of contracting the hepatitis B virus.

A study led by Stacy Tressler--who earned her doctorate in epidemiology from the West Virginia University School of Public Health--suggests that local health departments are vital to getting the hepatitis B vaccine to the people who need it most.

Her findings appear in the American Journal of Preventive Medicine.

"I don't think people realize the amount of health care that local health departments provide across West Virginia," Tressler said. "They really reach some of our most vulnerable populations, they do a lot of really great work and they've already built a lot of relationships in the community."

Now an epidemiologist with the Pennsylvania Department of Health, Tressler previously worked for the West Virginia Department of Health and Human Resources. During her 10 years of public health work in West Virginia, she "worked, for the most part, with local health departments. And the work that the local health departments do is really overlooked," she said.

Tressler and her colleagues at WVU analyzed data from local health department clinics that participated in the West Virginia Hepatitis B Vaccination Pilot Project. The pilot project distributed more than 10,000 doses of the hepatitis B vaccine to at-risk adults in West Virginia from 2013 to 2015.

The data encompassed 1,201 at-risk adults vaccinated at local health department clinics or through local health departments' outreach efforts to correctional facilities and substance use treatment centers.

Participants who received the vaccine at substance use treatment centers or local health departments' family planning clinics were significantly more likely to complete the series of injections--which consists of three shots--than people vaccinated at local health departments' sexually-transmitted-infection clinics.

"People who receive services through substance use treatment centers have a relationship with that facility," Tressler said. "Even if--for some reason--they're not in treatment anymore, I think those facilities can continue to work with people to try to get them the resources they need."

She credits these relationships--between facility staff members and the clients they serve--with increased odds of vaccine completion.

The researchers also found that participants vaccinated at substance use treatment centers, correctional facilities and local health departments' family planning clinics were much more likely to receive at least two doses of the hepatitis B vaccine.

That's important because it can be hard to get people to complete any vaccination that involves multiple shots, spread out over weeks or months. That's the case whether it's people with substance use disorders being vaccinated against the hepatitis B virus or middle-schoolers receiving the three-shot HPV vaccine.

"It's always a challenge getting people back in to finish the series--especially if you're trying to reach people who may have life circumstances that prevent them from engaging with the healthcare system," Tressler said. "There are going to be issues with trying to keep those people on your radar and being able to get them back in and to finish the series."

But even two doses of the three-dose hepatitis B vaccine impart some protection in most healthy adults. And in 2017, the Food and Drug Administration approved a new hepatitis B vaccine that requires just two shots.

"The high uptake of hepatitis B vaccine when health departments partnered with local drug treatment programs is very encouraging, as West Virginia has the highest rate of new hepatitis B infections in the U.S.," said Judith Feinberg, vice chair of research for the School of Medicine and a member of Tressler's research team. "People who are engaged in a treatment program have the opportunity to reliably receive the multiple vaccine doses required: three doses over six months for the older vaccine, and two doses over two months for a newer version."

The team also included School of Public Health researchers Christa Lilly, Diane Gross and Thomas Hulsey.

"This study shows that you can create partnerships with local health departments to provide healthcare for at-risk people," Tressler said. "People who may be at risk of contracting the hepatitis B virus might not access a primary care provider. You have to meet people where they are."
-end-
Citation

Title: Variations in Hepatitis B Vaccine Series Completion by Setting Among Adults at Risk in West Virginia

DOI: https://doi.org/10.1016/j.amepre.2020.05.022

Link: https://www.ajpmonline.org/article/S0749-3797(20)30272-5/fulltext

-WVU-

see/11/17/20

West Virginia University

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.